CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  OVERVIEW OF ACTIVITY
  Lung cancer is a devastating disease with a broad impact on public health as it accounts for approximately 13% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. A major focus of recent lung cancer research has been the development and subsequent approval of a number of molecular-targeted agents and the identification of related biomarkers to help guide treatment selection for patients with specific oncogenic alterations. Although the advent of these targeted treatments promises both efficacy and enhanced safety in the management of lung cancer, it also challenges practicing oncologists to appropriately select individuals who may benefit from these agents. In addition, clinical oncologists need to determine how to integrate such therapies into standard lung cancer treatment algorithms as they become available. Although several consensus- and evidence-based treatment guidelines are available to assist clinicians in making lung cancer treatment decisions, many areas of controversy persist in the academic and community settings. This CME program brings together leading clinical investigators and general oncologists to provide biological insights into the use of biomarkers and targeted therapy for patients with lung cancer. By reviewing the available clinical trial data and relevant case scenarios, this initiative will address gaps in medical knowledge and illuminate treatment ambiguities.
  
  LEARNING OBJECTIVES

  • Recall emerging research information and available guideline recommendations in the development of a genomic testing algorithm to optimize first- and later-line therapy for individuals with non-small cell lung cancer (NSCLC) according to their potential response or resistance to targeted therapy.
  • Evaluate the utility, limitations and current role of multiplex and next-generation sequencing platforms in guiding treatment decision-making for patients with NSCLC treated in the community setting.
  • Appraise recent FDA approvals and other therapeutic advances related to the long-term care of patients with metastatic NSCLC with EGFR tumor mutations, and discern how this information should be applied in clinical practice.
  • Consider the predictive utility of ALK mutation testing, and communicate the efficacy and safety of approved ALK inhibitors to appropriate patients with NSCLC.
  • Assess other oncogenic pathways (ie, ROS1, RET, MET, HER2, NTRK) mediating the growth of tumors in unique lung cancer subsets, and recall published research data with commercially available and experimental agents exploiting these targets.
  • Assess available clinical trial data with and the role of immune checkpoint inhibitors for patients with NSCLC with targetable genomic alterations.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Clinical Investigators
  
  Justin F Gainor, MD
  Director, Center for Thoracic Cancers
  Director of Targeted Immunotherapy, Termeer Center for Targeted Therapies
  Massachusetts General Hospital
  Assistant Professor, Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Oncorus, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: Adaptimmune, ALX Oncology, Array BioPharma Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, Novartis, Takeda Oncology, Tesaro, A GSK Company.
  
  Matthew Gubens, MD, MS
  Associate Professor, Thoracic Medical Oncology
  University of California, San Francisco
  San Francisco, California
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, BeyondSpring Inc, Bristol-Myers Squibb Company, Inivata; Contracted Research: Celgene Corporation, Merck, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.
  
  Geoffrey R Oxnard, MD
  Associate Professor of Medicine
  Dana-Farber Cancer Institute
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Dropworks, Foundation Medicine, GRAIL, Guardant Health, Illumina, Inivata, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Sysmex Corporation, Takeda Oncology; Contracted Research: GRAIL.
  
  Heather Wakelee, MD
  Professor of Medicine, Division of Oncology
  Faculty Director, Stanford Cancer Clinical Trials Office
  Stanford University School of Medicine
  Stanford Cancer Institute
  Stanford, California
  
  Consulting Agreements: Cellworks, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Helsinn Group, Janssen Biotech Inc, Merck, Mirati Therapeutics, Xcovery; Contracted Research: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Merck, Novartis, Pfizer Inc, Xcovery.
  
  Consulting Oncologists
  
  Isaac Levy, MD
  Memorial Healthcare System
  Hollywood, Florida
  
  No financial interests or affiliations to disclose.
  
  Estelamari Rodriguez, MD, MPH
  Associate Director for Community Outreach-Thoracic Oncology
  Sylvester Comprehensive Cancer Center
  University of Miami Miller School of Medicine
  Miami, Florida
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP; Speakers Bureau: Genentech, a member of the Roche Group.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Lilly and Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company.
  
  Release date: May 2020
  Expiration date: May 2021